Steven Cohen Corvus Pharmaceuticals, Inc. Transaction History
Point72 Asset Management, L.P.
- $42.2 Billion
- Q4 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 3,030,011 shares of CRVS stock, worth $13.7 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
3,030,011
Previous 5,562,729
45.53%
Holding current value
$13.7 Million
Previous $29.4 Million
46.36%
% of portfolio
0.04%
Previous 0.08%
Shares
9 transactions
Others Institutions Holding CRVS
# of Institutions
102Shares Held
38.1MCall Options Held
2.75MPut Options Held
1.17M-
Orbimed Advisors LLC San Diego, CA6.94MShares$31.3 Million0.98% of portfolio
-
Samlyn Capital, LLC New York, NY6.67MShares$30.1 Million0.56% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$14.8 Million18.22% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$12.1 Million0.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.45MShares$11.1 Million0.0% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $210M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...